FDA OKs Abbott CGMs for insulin automation

Today's Big News

Mar 6, 2023

Eisai, Biogen's high-stakes Leqembi filing nets FDA priority review—and an adcomm hearing 


Merck’s cardiovascular future takes shape as sotatercept overachieves, PCSK9 inhibitor passes phase 2 


Modified Abbott CGM sensors score FDA nod for use in automated insulin delivery systems


FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands 


Novartis ready to head for deep space with Voyager after a year 'kicking the tires' 


Sooma Medical’s neurostim device for at-home depression treatment lands FDA breakthrough tag

 

Featured

Eisai, Biogen's high-stakes Leqembi filing nets FDA priority review—and an AdComm hearing

After scoring an accelerated approval for Alzheimer's disease drug Leqembi in January, Eisai and Biogen hope to turn that into a traditional approval by July 6. But an advisory committee will get a chance to vote on the drug first.
 

Top Stories

Merck’s cardiovascular future takes shape as sotatercept overachieves, PCSK9 inhibitor passes phase 2

Merck & Co. has looked to its mid-to-late stage cardiovascular pipeline as a potential goldmine amid the race to replace Keytruda's revenue stream. And a handful of new readouts provide a glimpse into the promise the company is banking on.

Modified Abbott CGM sensors score FDA nod for use in automated insulin delivery systems

As diabetes device makers race to build completely hands-off artificial pancreas systems, Abbott’s continuous glucose monitors are getting a significant upgrade.

FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands

Thanks to two FDA nods, Eli Lilly's Verzenio doesn't need results from a biomarker test to treat certain patients with early breast cancer, and it has followed Pfizer's Ibrance with an expanded use in the metastatic setting in women regardless of menopausal status.

Novartis ready to head for deep space with Voyager after a year 'kicking the tires'

It’s been a year since Novartis ventured into orbit with Voyager Therapeutics to find new central nervous system targets. Now, the Big Pharma is ready to go deeper into space with the AAV capsid discovery biotech.

Sooma Medical’s neurostim device for at-home depression treatment lands FDA breakthrough tag

According to a study published last year, after an average of 16 sessions with Sooma Medical’s device, just over half of 410 participants saw their depressive symptoms reduced by at least 50%.

Incyte's LIMBER lumbers to early end as analysis shows Jakafi cancer combo destined to fail

Incyte’s first bid to build a better Jakafi regimen is banjaxed. A phase 3 trial of parsaclisib and Jakafi has come screeching to a halt ahead of schedule after the independent data monitoring committee found it was on course to fail.

ACC23: J&J's combo pill of Opsumit plus tadalafil improves blood flow in PAH patients

Johnson & Johnson's Opsynvi—which consists of 10 mg of Opsumit (macitentan) and 40 mg of Adcirca (tadalafil)—significantly improved blood flow versus macitentan or tadalafil as monotherapies for the treatment of patients with pulmonary arterial hypertension.

ACC23: Bayer and J&J's Xarelto reduces ischemia risk for PAD patients after revascularization surgery

When added to aspirin, Bayer and Johnson & Johnson’s Xarelto reduced the risk of acute limb ischemia by 33% in patients with peripheral artery disease who had lower extremity revascularization surgery. Results from a prespecified analysis of a phase 3 study were presented at the American College of Cardiology’s 72nd Annual Scientific Session.

FDA clears Galaxy robotic surgery system, sending lung cancer diagnosis to a new frontier

A surgical robot system developed by Noah Medical and newly cleared by the FDA is out of this world—or, at least, the current world of bronchoscopy procedures.

To 'keep pace with viral evolution,' Invivyd is also evolving (again)

Invivyd, which was launched in the early days of the pandemic under the name Adagio to find treatments for COVID-19, is hoping the third monoclonal antibody is the charm.
 
Fierce podcasts

Don't miss an episode

'The Top Line': The surprising multibillion-dollar medtech megadeals

This week on "The Top Line," we discuss 2022's M&A trends in the medtech sector and the surprising multibillion-dollar megadeals. We also cover the top headlines from this week.
 

Resources

Executive Summary

Optimizing drug discovery in a fast-moving market

Read about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines.
Whitepaper

Answering your specific questions about mRNA/saRNA manufacturing

Have you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here.
Whitepaper

Proven Pharmaceutical Go-To-Market Model

Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success.

Research

Strategizing for Clinical Trial Diversity

Like many top 10 and global pharma companies, an H1 client needed to diversify both its patient outreach and site investigator profiles for upcoming trials.
Whitepaper

The Power of Small & Safety: Nanoplasmid™️ Vector Platform

Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies.

Whitepaper

Leveraging Archetypes for Effective Launch Strategy

Learn more about critical success factors for your next launch based on the experience of 100+ pharma product launches.
On-Demand Webinar

Writing the Future of Antibody Discovery Solutions

See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions.

Whitepaper

Intranasal Drug Product Development: Formulation to Manufacturing

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?
Whitepaper

Running Decentralized Trials at Scale

Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment.
Research

Step-wise strategy to address process characterization and late phase development

Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development.

Case Study

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

Whitepaper

Designing an Optimal APAC Clinical Supply Chain

Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific.
Whitepaper

Key Clinical Supply Issues Sponsors Should Consider with their CRO

As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs.

Research

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

Whitepaper

Specialized Expertise for Management of Clinical Supply Budgets

For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Roles and Responsibilities of Specialized Clinical Supply Experts

How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis.
Whitepaper

Questions You Need to Ask Your CRO About Clinical Supply

Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial.
Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
 

Industry Events

 

Upcoming Fierce Events

14-15
Mar
San Francisco, CA
20-22
Mar
West Palm Beach, FL
3-4
Apr
San Diego, CA
1-3
May
May 1-3, 2023 | Jersey City, NJ
23
May
Free Virtual Event

View all events